Bibliographical note

Funding Information:
We would like to thank all workshop participants for sharing their expertise and insights on the topic of TTS and VITT including the workshop presenters: Nicolas Praet, Kerstin Luhn, Nadia Foskett, and Taylor Cohen, who shared data on behalf of the marketing authorization holders for adenovirus vector COVID-19 vaccines.

Funding Information:
M.B. declared a research grant to institution from AstraZeneca for clinical study. A.P. reported pending/issued patents in the area of anti-PF4 antibodies, HIT, VITT and platelet storage (assigned to Mayo Clinic, Retham Technologies, and Versiti Blood Center of Wisconsin), equity ownership in and serving as an officer of Retham Technologies, and member of the advisory board of Veralox Therapeutics. D.P.A. receives funding from the UK National Institute for Health and Care Research (NIHR) in the form of a senior research fellowship and from the Oxford NIHR Biomedical Research Centre. His research group has received funding from the European Medicines Agency and Innovative Medicines Initiative. His research group has received research grant/s from Amgen, Chiesi-Taylor, GSK, Novartis, and UCB Biopharma. His department has also received advisory or consultancy fees from Amgen, Astellas, Astra Zeneca, Johnson and Johnson, and UCB Biopharma; and speaker fees from Amgen and UCB Biopharma. Janssen and Synapse Management Partners have supported training programmes organised by DPA’s department and open for external participants organized by his department outside the submitted work. AG has received funding from the European Medicines Agency and reports consulting fees from: Aspen, Bayer Vital, Chromatec, Instrumentation Laboratory, Macopharma, Sanofi-Aventis, Roche, GTH e.V., Mylan Germany, Takeda Pharma, Falk Foundation e.V., Dilaflor, outside of this work. Also, AG has a patent Screening Methods for transfusion related acute lung injury (TRALI) with royalties paid to EP2321644, 18.05.2011. All the other authors declared no competing interests.